HOME >> MEDICINE >> NEWS
AMPAKINE compounds a new potential treatment for respiratory depression

was intended.

The drug tested in this study belongs to a novel class of molecules known as AMPAKINE compounds being developed by Cortex Pharmaceuticals, Inc. located in Irvine, California. AMPAKINE compounds act on the most common excitatory receptor in the brain, the AMPA "Glutamate type receptor," which has been shown in rodent models to boost the brain's own protein for improving age-related deficits in memory mechanisms. In primate models AMPAKINE compounds have replicated the studies in rodents and in adults patients suffering from Attention Deficit Hyperactivity Disorder, significant clinical and statistical improvement in increase attention and decrease hyperactivity have been observed. The U. Alberta research provide evidence that another important AMPAKINE indication is to stimulate primitive areas of the brain called the pre-Botzinger Complex responsible for breathing, without causing side effects. The pre-Botzinger Complex generated respiratory-related oscillations similar to those generated by the whole brainstem in vitro, and neurons with voltage-dependent pacemaker-like properties that have been identified in this brain region.

In a study published in 2006, Dr. John J. Greer of U. Alberta demonstrated that certain AMPAKINE compounds enhance the respiratory drive and breathing rhythm at the brain-stem level containing the pre-Botzinger Complex in laboratory rats whose respiration rates were purposely suppressed by administration of central nervous system depressants.

Dr. Greer found that respiratory depression induced by these agents can be reversed or prevented in test animals with an experimental AMPAKINE drug, without a reduction of pain relief or sedation.

Greer and coworkers treated rats with the opioids analgesic fentanyl or the barbiturate sedative Phenobarbital, both commonly prescribed in the United States. Greer used a technique known as plethysmography, which measures blood flow throughout
'"/>

Contact: Mark Varney
mvarney@cortexpharm.com
949-231-0672
Cortex Pharmaceuticals
4-Jun-2007


Page: 1 2 3 4 5

Related medicine news :

1. New oxidation methods streamline synthesis of important compounds
2. Depression among retired NFL players: Rates mirror the general public, but pain compounds symptoms
3. U of M researchers discover compounds to shrink tumors
4. Diagnosis and treatment of osteoporosis falls shortnon adherence compounds issue
5. New compounds fight chronic symptoms of bowel disorders
6. New synthetic compounds appear to prevent brain cell death
7. Phenolic compounds may explain Mediterranean diet benefits
8. Vitamin D compounds show promise for prevention of prostate cancer
9. Hebrew University researcher develops compounds to control bacteria
10. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
11. Electric fields have potential as a cancer treatment

Post Your Comments:
(Date:11/26/2014)... 25, 2014 (HealthDay News) -- Parents need to take ... concussions, an expert warns. Parents must make sure ... standard, Dr. David Dodick, chair of the American Migraine ... Clinic College of Medicine in Scottsdale, Ariz. in an ... release. Any coach involved with teens sports needs ...
(Date:11/24/2014)... 24, 2014 Global electrophysiology devices ... by 2020, according to a new study by ... cardiac arrhythmias clubbed with growing global geriatric population ... Though still in the budding stage, the electrophysiology ... usage rates in the recent times, with physicians ...
(Date:11/24/2014)... Residents of retirement communities in Ohio and ... GOT TALENT, an annual online talent competition and showcase ... classic crooners, to seniors partying on a “night on ... living young. , “SENIORS GOT TALENT, while still having ... has always been about highlighting the vibrancy of being ...
(Date:11/24/2014)... Westbury, New York (PRWEB) November 24, 2014 ... recently contacted by the Family and Children's Association ... products such as soap, shampoo, mouthwash and other such ... senior citizens who are home bound, living in nursing ... are intended to greatly enhance the well being of ...
(Date:11/24/2014)... 2014 SafeHandles™ announced that they will ... Ed Begley Jr, airing via Discovery Channel. Dates and ... a passive, non-invasive, replaceable, and affordable germ protective device. ... shrinkable sleeves and adhesives to promote hand hygiene in ... core of SafeHandles is the desire to make a ...
Breaking Medicine News(10 mins):Health News:Parents Need to Take Lead on Teen Concussion Prevention 2Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 2Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 3Health News:Electrophysiology Devices Market Worth Forecasted To Reach $6.19 Billion By 2020: Grand View Research, Inc. 4Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 2Health News:Nursing Homes & Assisted Living Retirement Communities Enter Seniors Guide's Seniors Got Talent 3Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2
(Date:11/26/2014)... , Nov. 25, 2014 Halozyme Therapeutics, Inc. (NASDAQ: ... Jaffray Healthcare Conference in New York ... PDT . Dr. Helen Torley , President and ... The presentation will be webcast through the "Investors" section of ... will be made available for 90 days following the event. ...
(Date:11/24/2014)... (NYSE: CRY ), a leading medical device and ... today that it will participate in the upcoming 26 th ... 2014 at The New York Palace Hotel in ... of the Company,s presentation is scheduled to begin at 1:30 ... by Pat Mackin , President and Chief Executive Officer.The ...
(Date:11/24/2014)... Nov. 24, 2014 /PRNewswire/ - Milestone Pharmaceuticals, Inc. today ... in Melbourne, Australia of ... potential treatment of paroxysmal supraventricular tachycardia (PSVT).  The ... was well tolerated at single doses up to ... profile, desirable PK properties including rapid onset, and ...
Breaking Medicine Technology:Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 2CryoLife to Present at 26th Annual Piper Jaffray Healthcare Conference 3Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 2Milestone Announces Positive Phase 1 Data for MSP-2017; Supports Advancement into Phase 2 in PSVT Patients 3
Cached News: